December 3, 2022, Shanghai - Today marked the online convening of the 2022 China Healthcare Summit of Entrepreneurs, Scientists and Investors (CHSESI). This event was jointly organized by China Pharmaceutical Enterprises Association, China Medical Biotech Association, General Office of the Central Committee of the Chinese Peasants and Workers Democratic Party, and Hangzhou Investment Promotion Bureau. During the conference, the prestigious “2022 Top 100 China Pharmaceutical Innovation Seed Enterprises” list was unveiled, recognizing outstanding companies in pharmaceutical innovation. KeChow Pharma earned a spot on this list, celebrating its exceptional performance in innovative drug R&D in China. Dr. Tian Hongqi, Chairman and CEO of KeChow Pharma, participated in the online award ceremony.

KeChow Pharma is dedicated to the R&D of targeted anti-cancer drugs with independent intellectual property rights, driven by scientific innovation and a commitment to providing best-in-class medications to meet clinical needs. Notably, in 2022, KeChow’s first independently developed targeted anti-cancer drug, HL-085, reached the primary clinical endpoint in its registration clinical trial and is poised for NDA submission. The initial indication for HL-085 is with NRAS-mutant melanoma, a condition for which no approved treatment currently exists worldwide. HL-085 is poised to become the first targeted drug approved for this indication globally and the first MEK inhibitor to be marketed in China.

Dr. Tian Hongqi expressed: “It is an honor for KeChow Pharma to be recognized as one of the ‘2022 Top 100 China Pharmaceutical Innovation Seed Enterprises’. We remain committed to advancing and launching high-quality innovative drugs to benefit patients worldwide.” 

In 2022, Healthcare Executive released its “Top 100 Seed Companies” list, selecting from over 5,000 Chinese pharmaceutical firms based on Derwent™ patent data, and Cortellis™ Competitive Intelligence and Clinical Trial data. This involved digitizing metrics such as the number of granted patents, total patent citations, clinical trials in progress, and newly approved and launched drugs. The candidates are primarily biotech firms with unique, innovative products and technologies. Although these companies have not yet entered the public capital market, they represent a strong reserve force for advancing pharmaceutical innovation in China.

About KeChow Pharma

KeChow Pharma is dedicated to developing innovative treatments for tumors, free radical-related diseases, and other therapeutic areas. Its pipeline includes MEK inhibitor, chemoprotective agents, KRASG12C inhibitor, pan-RAF inhibitor, and multiple other tumor-targeted inhibitors. Notably, its MEK inhibitor, Tunlametinib (HL-085), has submitted a new drug application in China and is included in the CSCO guidelines. Another novel drug, a chemoprotective agent, demonstrates superior efficacy and safety compared to current clinical counterparts. All research efforts aim to address unmet clinical needs globally and within China by developing original small molecule drugs with “best-in-class” potential, bridging domestic gaps and fulfilling scientific aspirations to enhance quality of life.